Canaccord Genuity Maintains Buy on Fractyl Health, Lowers Price Target to $39

Benzinga · 3d ago
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and lowers the price target from $96 to $39.